Clinical trials: Patients With Advanced Solid Tumors
Advanced Solid Tumors
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of single agent of IBI310, and in combination of sintilimab, in patients…
- Trial name
- NCT03545971
- Testing
- IBI310, Sintilimab
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally.
- Conditions
- Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma
- Trial name
- NCT05415098
- Testing
- APG-5918
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Solid Tumors, Multiple Myeloma
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene…
- Conditions
- Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors
- Trial name
- NCT02110563
- Testing
- DCR-MYC
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
HER2-Positive Advanced Biliary Tract Cancer
An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer
This is an intermediate-size Expanded Access Protocol (EAP) for use of zanidatamab (ZW25) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced biliary tract cancer (BTC) who are not eligible for…
- Trial name
- NCT04578444
- Testing
- Zanidatamab
- Where
- 17 sites in United States, France and 3 more
- Sponsor
- Jazz Pharmaceuticals
Solid Tumor Cancer, Metastases
Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors
This study evaluates a non-cationic peptide-CD47 siRNA nanocomplex for refractory advanced solid tumors. The candidate blocks the CD47-SIRPα "don't eat me" signal, repolarizes tumor-associated macrophages, and restores antitumor…
- Conditions
- Solid Tumor Cancer, Metastases, Head and Neck Cancer
- Trial name
- NCT07583914
- Testing
- NCP-CD47 siRNA intratumorally injection
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Solid Tumor
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate…
- Trial name
- NCT06234098
- Testing
- AT-1965 Liposome Injection
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alyssum Therapeutics
Unspecified Adult Solid Tumor, Protocol Specific
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00372736
- Testing
- AEG35156, docetaxel, protein expression analysis
- Where
- 3 sites in Canada
- Volunteers
- 27 people
- Sponsor
- NCIC Clinical Trials Group
Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the…
- Conditions
- Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
- Trial name
- NCT05768932
- Testing
- BAL0891, Tislelizumab, Paclitaxel
- Where
- 17 sites in United States, South Korea
- Volunteers
- 260 people
- Sponsor
- SillaJen, Inc.
Solid Tumor
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment, nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M08D1 for…
- Trial name
- NCT06718621
- Testing
- BL-M08D1
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Thrombocytopenia, Radiotherapy Side Effect
Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy
Thrombocytopenia represents one of the main toxicities of concurrent chemoradiotherapy, which may necessitate chemotherapy dose reductions, dose delays, or discontinuation, and even compromise survival.
- Trial name
- NCT06433830
- Testing
- Hetrombopag Olamine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sir Run Run Shaw Hospital
Advanced Malignant Solid Tumor
Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 in combination with SCTB39-1with or without standard therapy in adult patients with advanced…
- Trial name
- NCT07594028
- Testing
- SCTB41+SCTB39-1
- Volunteers
- 126 people
- Sponsor
- Sinocelltech Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00520000
- Testing
- Carboplatin, Abraxane
- Volunteers
- 47 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced Solid Tumor, Non-small Cell Lung Cancer
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM2520 in subjects with advanced…
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT05780307
- Testing
- IMM2520
- Where
- China
- Volunteers
- 48 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Solid Tumor
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of humanized anti-PD-1 monoclonal antibody, HLX10, in patients with advanced or metastatic tumors refractory to…
- Trial name
- NCT03468751
- Testing
- HLX10
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Henlix, Inc
Solid Tumor
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
SYD985.004 is a two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib aimed at evaluating safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or…
- Trial name
- NCT04235101
- Testing
- SYD985 + Niraparib
- Where
- 6 sites in Belgium, Netherlands and 1 more
- Volunteers
- 32 people
- Sponsor
- Byondis B.V.
Advanced or Metastatic Solid Tumors
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate (ADC) in participants with advanced or metastatic solid…
- Trial name
- NCT06752681
- Testing
- DAY301
- Where
- 11 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Advanced Solid Tumors
Safety Study of X-82 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) of X-82 as a single agent.
- Trial name
- NCT01296581
- Testing
- X-82
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Tyrogenex
Solid Tumor, Adult
A Study of TIL in Advanced Solid Tumors (CZ)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections and infused i.v.
- Trial name
- NCT07294872
- Testing
- GC101TIL
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Juncell Therapeutics
MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer
Evaluation of XYA02 in Patients With Advanced Solid Tumors
This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.
- Conditions
- MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ Adenocarcinoma
- Trial name
- NCT07670312
- Testing
- XYA02
- Where
- 5 sites in Australia
- Volunteers
- 190 people
- Sponsor
- XYone Therapeutics, Inc
Advanced Solid Tumors
HWS116 Monotherapy in Patients With Advanced Solid Tumors
This is a Phase I open-label study that will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HWS116 monotherapy in patients with advanced solid tumors.
- Trial name
- NCT07413328
- Testing
- HWS116 Injection
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.